Pacira BioSciences (PCRX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | -81.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -81.08% |
| Mar 31, 2026 | 175.86% |
| Dec 31, 2025 | 5,353.53% |
| Sep 30, 2025 | 183.61% |
| Jun 30, 2025 | 508.56% |
| Mar 31, 2025 | -65.03% |
| Dec 31, 2024 | -104.39% |
| Sep 30, 2024 | -1,101.36% |
| Jun 30, 2024 | -307.68% |
| Mar 31, 2024 | -123.47% |
| Dec 31, 2023 | -25.16% |
| Sep 30, 2023 | 90.86% |
| Jun 30, 2023 | -61.77% |
| Mar 31, 2023 | 131.82% |
| Dec 31, 2022 | -83.28% |
| Sep 30, 2022 | -35.46% |
| Jun 30, 2022 | 531.75% |
| Mar 31, 2022 | -273.70% |
| Dec 31, 2021 | 181.29% |
| Sep 30, 2021 | 82.71% |